New data on sebeltralstat to be presented at forthcoming European scientific meeting
The findings of six abstracts on sebeltralstat, which is currently undergoing testing amongst HAE patients, have been accepted for presentation at the forthcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress. Details of the abstract which will be presented were shared with HAEi:
- Potential for Sebetralstat to Address Pseudo-allergic Reaction Burden Secondary to Icatibant in HAE
- Psychological Burden Associated with Injectable HAE On-Demand Treatments: A Patient and Caregiver Interview Study
- Sebetralstat for Treatment of HAE Attacks in Patients Receiving Berotralstat, Lanadelumab, or C1 Inhibitor for Long-term Prophylaxis: Interim Analysis from KONFIDENT-S
- Adherence to Long-Term Prophylaxis for Hereditary Angioedema and the Impact on On-demand Treatment Claims in the US
- Anxiety Associated with Parenteral On-Demand Treatment for Hereditary Angioedema Attacks in Patients from Italy
- Impact of Delayed Treatment of Hereditary Angioedema Attacks: Insights from Patient Surveys Across France, the United Kingdom, and the United States
(Source: KalVista)